SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-20-002596
Filing Date
2020-08-10
Accepted
2020-08-10 16:05:20
Documents
37
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT cns_10q-063020.htm 10-Q 255593
2 CERTIFICATION BY CHIEF EXECUTIVE OFFICER cns_ex3101.htm EX-31.1 6984
3 CERTIFICATION BY CHIEF FINANCIAL OFFICER cns_ex3102.htm EX-31.2 6935
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3201.htm EX-32.1 3176
5 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3202.htm EX-32.2 3422
  Complete submission text file 0001683168-20-002596.txt   1690866

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE cnsp-20200630.xml EX-101.INS 235442
7 XBRL SCHEMA FILE cnsp-20200630.xsd EX-101.SCH 19813
8 XBRL CALCULATION FILE cnsp-20200630_cal.xml EX-101.CAL 27897
9 XBRL DEFINITION FILE cnsp-20200630_def.xml EX-101.DEF 83147
10 XBRL LABEL FILE cnsp-20200630_lab.xml EX-101.LAB 173766
11 XBRL PRESENTATION FILE cnsp-20200630_pre.xml EX-101.PRE 138924
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 201089333
SIC: 2834 Pharmaceutical Preparations